Advances in Biased Opioid Agonists for Analgesia: Side Effects Minimisation and Addiction Prevention

Kaiyun Zhang

doi:10.62051/ijphmr.v5n3.02

Authors

Kaiyun Zhang

DOI:

https://doi.org/10.62051/ijphmr.v5n3.02

Keywords:

Biased agonist, Opioid receptor, Analgesia, Novel analgesic, Opioid-induced adverse effect, Opioid use disorder

Abstract

Opioids, as frontline analgesics, are associated with substantial adverse effects. For example, μ-opioid receptor agonists commonly cause respiratory depression and carry high addictive potential, while κ-opioid receptor agonists can produce depression-like reactions and aversion. The introduction of biased agonism has offered a strategy to dissociate opioid-induced adverse effects from analgesic efficacy. In recent years, biased agonists developed for different opioid receptor types have shown promise in reducing side effects, lowering addictive liability, and achieving analgesia with improved therapeutic windows, suggesting the possibility of a safer next generation of analgesics. However, important obstacles and challenges remain.

References

[1] Kosten, T. R., & George, T. P. (2002) The neurobiology of opioid dependence: implications for treatment. Science & practice perspectives, 1(1): 13.

[2] Ramirez, J. M., Burgraff, N. J., & Wei, A. D. et al. (2021) Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding. Journal of Neurophysiology.

[3] Rankovic, Z., Brust, T. F., & Bohn, L. M. (2016) Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorganic & medicinal chemistry letters, 26(2): 241-250.

[4] Zhang, P., Johnson, P. S., & Zöllner, C. et al. (1999) Mutation of human μ opioid receptor extracellular “disulfide cysteine” residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Molecular brain research, 72(2): 195-204.

[5] Sobczak, M., Sałaga, M., & Storr, M. A. et al. (2014) Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. Journal of gastroenterology, 49(1): 24-45.

[6] Lambert, D. G. (2023) Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis. BJA open, 6: 100141.

[7] Al-Hasani, R., & Bruchas, M. R. (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology, 115(6): 1363.

[8] Mafi, A., Kim, S. K., & Goddard III, W. A. (2020) Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor. Proceedings of the National Academy of Sciences, 117(28): 16346-16355.

[9] Tian, X., Kang, D. S., & Benovic, J. L. (2013) β-arrestins and G protein-coupled receptor trafficking. Arrestins-Pharmacology and therapeutic potential, 173-186.

[10] Marchese, A., Paing, M. M., & Temple, B. R. et al. (2008) G protein–coupled receptor sorting to endosomes and lysosomes. Annu. Rev. Pharmacol. Toxicol., 48(1): 601-629.

[11] T Andresen, B. (2011) A pharmacological primer of biased agonism. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 11(2): 92-98.

[12] Doll, C., Konietzko, J., & Pöll, F. et al. (2011) Agonist‐selective patterns of µ‐opioid receptor phosphorylation revealed by phosphosite‐specific antibodies. British journal of pharmacology, 164(2): 298-307.

[13] Edinoff, A. N., Kaplan, L. A., & Khan, S. et al. (2021) Full opioid agonists and tramadol: pharmacological and clinical considerations. Anesthesiology and Pain Medicine, 11(4): e119156.

[14] Imam, M. Z., Kuo, A., & Ghassabian, S. et al. (2018) Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology, 131: 238-255.

[15] Soergel, D. G., Subach, R. A., & Burnham, N. et al. (2014) Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain, 155(9): 1829-1835.

[16] Viscusi, E. R., Webster, L., & Kuss, M. et al. (2016) A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain, 157(1): 264-272.

[17] Viscusi, E. R., Skobieranda, F., & Soergel, D. G. et al. (2019) APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. Journal of pain research, 927-943.

[18] Singla, N. K., Skobieranda, F., & Soergel, D. G. et al. (2019) APOLLO‐2: a randomized, placebo and active‐controlled phase III study investigating oliceridine (TRV 130), a G protein–biased ligand at the μ‐opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Practice, 19(7): 715-731.

[19] Negus, S. S., & Freeman, K. B. (2018) Abuse potential of biased mu opioid receptor agonists. Trends in pharmacological sciences, 39(11): 916-919.

[20] Manglik, A., Lin, H., & Aryal, D. K. et al. (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature, 537(7619): 185-190.

[21] Kudla, L., Bugno, R., & Skupio, U. et al. (2019) Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine. British Journal of Pharmacology, 176(23): 4434-4445.

[22] Stiefel, K. M., Merrifield, A., & Holcombe, A. O. (2014) The claustrum’s proposed role in consciousness is supported by the effect and target localization of Salvia divinorum. Frontiers in integrative neuroscience, 8: 20.

[23] Tejeda, H. A., Wang, H., & Flores, R. J. et al. (2021) Dynorphin/kappa-opioid receptor system modulation of cortical circuitry. The Kappa Opioid Receptor, 223-253.

[24] Pan, Z. Z. (1998) μ-Opposing actions of the κ-opioid receptor. Trends in pharmacological sciences, 19(3): 94-98.

[25] El Daibani, A., Paggi, J. M., & Kim, K. et al. (2023) Molecular mechanism of biased signaling at the kappa opioid receptor. Nature communications, 14(1): 1338.

[26] Bruchas, M. R., Macey, T. A., & Lowe, J. D. et al. (2006) Kappa opioid receptor activation of p38 MAPK is GRK3-and arrestin-dependent in neurons and astrocytes. Journal of Biological Chemistry, 281(26): 18081-18089.

[27] Ehrich, J. M., Messinger, D. I., & Knakal, C. R. et al. (2015) Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons. Journal of Neuroscience, 35(37): 12917-12931.

[28] Inui, S. (2015) Nalfurafine hydrochloride to treat pruritus: a review. Clinical, cosmetic and investigational dermatology, 249-255.

[29] Schattauer, S. S., Kuhar, J. R., & Song, A. et al. (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cellular signalling, 32: 59-65.

[30] Kozono, H., Yoshitani, H., & Nakano, R. (2018) Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus. International Journal of Nephrology and Renovascular Disease, 9-24.

[31] Lazenka, M. L., Moerke, M. J., & Townsend, E. A. et al. (2018) Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats. Psychopharmacology, 235(1): 203-213.

[32] Brust, T. F., Morgenweck, J., & Kim, S. A. et al. (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Science signaling, 9(456): ra117-ra117.

[33] Ranjan, R., Pandey, S., & Shukla, A. K. (2017) Biased opioid receptor ligands: gain without pain. Trends in Endocrinology & Metabolism, 28(4): 247-249.

[34] Zamarripa, C. A., Pareek, T., & Schrock, H. M. et al. (2021) The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats. Psychopharmacology, 238(12): 3463-3476.

[35] Huskinson, S. L., Platt, D. M., & Zamarripa, C. A. et al. (2022) The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys. Pharmacology Biochemistry and Behavior, 217: 173394.

[36] Liu-Chen, L. Y., & Huang, P. (2022) Signaling underlying kappa opioid receptor-mediated behaviors in rodents. Frontiers in Neuroscience, 16: 964724.

[37] Dalefield, M. L., Scouller, B., & Bibi, R. et al. (2022) The kappa opioid receptor: a promising therapeutic target for multiple pathologies. Frontiers in pharmacology, 13: 837671.

[38] Peppin, J. F., & Raffa, R. B. (2015) Delta opioid agonists: a concise update on potential therapeutic applications. Journal of clinical pharmacy and therapeutics, 40(2): 155-166.

[39] Conibear, A. E., Asghar, J., & Hill, R. et al. (2020) A novel G protein–biased agonist at the δ opioid receptor with analgesic efficacy in models of chronic pain. The Journal of Pharmacology and Experimental Therapeutics, 372(2): 224-236.

[40] Cheng, L., Miao, Z., & Liu, S. et al. (2024) Cryo-EM structure of small-molecule agonist bound delta opioid receptor-Gi complex enables discovery of biased compound. Nature Communications, 15(1): 8284.